71289-64-0

Basic information

• Product Name: 3-[(2,4-DICHLOROBENZYL)OXY]BENZALDEHYDE
• Synonyms: OTAVA-BB BB7018802029;3-[(2,4-DICHLOROBENZYL)OXY]BENZALDEHYDE;AKOS B014304;CHEMBRDG-BB 3014304;ASISCHEM N40488;ART-CHEM-BB B014304;Albb-001431;3-[(2,4-dichlorobenzyl)oxy]benzaldehyde(SALTDATA: FREE)
• CAS NO: 71289-64-0
• Molecular Formula: C₁₄H₁₀Cl₂O₂
• Molecular Weight: 281.13
• Mol File: 71289-64-0.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 412.9°C at 760 mmHg
• Flash Point: 169.6°C
• Appearance: /
• Density: 1.34g/cm³
• Vapor Pressure: 5.01E-07mmHg at 25°C
• Refractive Index: 1.623
• CAS DataBase Reference: 3-[(2,4-DICHLOROBENZYL)OXY]BENZALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-[(2,4-DICHLOROBENZYL)OXY]BENZALDEHYDE(71289-64-0)
• EPA Substance Registry System: 3-[(2,4-DICHLOROBENZYL)OXY]BENZALDEHYDE(71289-64-0)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22-36
• Safety Statements: 26
• HazardClass: IRRITANT
• Hazardous Substances Data: 71289-64-0(Hazardous Substances Data)

Usage

General Description

3-[(2,4-DICHLOROBENZYL)OXY]BENZALDEHYDE is a chemical compound with the molecular formula C14H10Cl2O2. It is a benzaldehyde derivative with two chlorine atoms attached to the benzyl group. The compound is commonly used as an intermediate in the synthesis of various pharmaceuticals and organic compounds. It is also known for its wide range of biological and pharmacological activities, including its potential as an anti-tumor and anti-inflammatory agent. Additionally, 3-[(2,4-DICHLOROBENZYL)OXY]BENZALDEHYDE has been studied for its potential use in the development of new drugs and therapies for various diseases, making it a valuable compound in the field of medicinal chemistry.

InChI:InChI=1/C14H10Cl2O2/c15-12-5-4-11(14(16)7-12)9-18-13-3-1-2-10(6-13)8-17/h1-8H,9H2

Upstream product

• 94-99-5 2,4-Dichlorobenzyl chloride 
• 100-83-4 meta-hydroxybenzaldehyde 

Downstream Products

• 467451-33-8 (Z)-5-(3-((2,4-dichlorobenzyl)oxy)benzylidene)-2-thioxoimidazolidin-4-one 
• 71289-83-3 1-[3-(2,4-Dichloro-benzyloxy)-phenyl]-butan-1-ol 

Relevant articles and documents

Computer-Aided Search for 5-Arylideneimidazolone Anticancer Agents Able To Overcome ABCB1-Based Multidrug Resistance

ABCB1 modulation is an interesting strategy in the search for new anticancer agents that can overcome multidrug resistance (MDR). Hence, 17 new 5-arylideneimidazolones containing an amine moiety, as potential ABCB1 inhibitors, were designed, synthesized, and investigated. The series was tested in both parental (PAR) and multidrug-resistant (MDR) ABCB1-overexpressing T-lymphoma cancer cells using cytotoxicity assays. The ABCB1-modulating activity was examined in rhodamine 123 accumulation tests, followed by Pgp-Glo Assay to determine the influence of the most active compounds on ATPase activity. Lipophilic properties were assessed both, in silico and experimentally (RP-TLC). Pharmacophore-based molecular modelling toward ABCB1 modulation was performed. The studies allowed the identification of anticancer agents (p-fluorobenzylidene derivatives) more potent than doxorubicin, with highly selective action on MDR T-lymphoma cells (selectivity index >40). Most of the investigated compounds showed ABCB1-modulating action; in particular, two 5-benzyloxybenzylidene derivatives displayed activity nearly as strong as that of tariquidar.

Synthesis and biological evaluation of dihydrotriazine derivatives as potential antibacterial agents

A series of 1,4-dihydro-1,3,5-triazine derivatives were designed and synthesized and their antibacterial and antifungal activities were evaluated. Most of the synthesized compounds showed potent inhibition of several Gram-positive bacterial strains (including multidrug-resistant clinical isolates) and Gram-negative bacterial strains, with minimum inhibitory concentrations (MICs) in the range of 2.1–181.2?μmol/L. Compounds 7a and 7c presented the most potent inhibitory activities against Gram-positive bacteria (e.g., Staphylococcus aureus 4220), Gram-negative bacteria (e.g., Escherichia coli 1924), and the fungus Candida albicans 7535, with MICs of 2.1 or 4.1?μmol/L. Especially, compound 7a was the most potent, with an MIC of 2.1?μmol/L against four multidrug-resistant, Gram-positive bacterial strains. The cytotoxic activity of the compound 7a, 7c and 7f was assessed in HepG2 cells, and the results suggest that 1,4-dihydro-1,3,5-triazine derivatives bearing a 6-benzyloxynaphthalen moiety are interesting scaffolds for the development of novel antibacterial agents.

Antifungal imidazole derivatives. III. Benzylic ethers of (1-imidazolylmethyl)-phenols

-